Everest Medicines Enters into Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases, Driving Value Conversion
HONG KONG, Jun 4, 2026 – (ACN Newswire) – Everest Medicines (HKEX 1952.HK) announced that it…
i10X launches Superagent
CTO Confidence in Scaling AI Falls for Third Straight Year, Akkodis Report Finds
CTO Confidence in Scaling AI Falls for Third Straight Year, Akkodis Report Finds
Anker Innovations announces the listing plan on the Main Board of HKEX with a maximum fundraising of HK$4,631.6 Million*